All lobbying filings

TIBER CREEK GROUP

Lobbying for JAZZ PHARMACEUTICALS · â€‹Biopharmaceutical company.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · California · House · Senate · $50,000.00 income · posted Apr 18, 2026

Official filing document

Bills named in this filing 2

HR 4121
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026
S 2256
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026

Lobbying activity 3

Health Issues

Issues related to the FDA and Health and Human Services pertaining to CBD policies; Issues related to the regulation of intoxicating hemp.

Medical/Disease Research/Clinical Labs

Issues related to cannabis research; Issues related to the FDA; Issues related to cannabis research at Health and Human Services.

Budget/Appropriations

Issues related to FDA enforcement of non-FDA approved, cannabis derived CBD products in H.R. 4121/S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026; Issues related to the Ag/FDA amendment - technical correction to hemp in H.R. 4121/S. 2256 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026; Issues related to intoxicating hemp products.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.